Danaher Co. (NYSE:DHR) Shares Acquired by Salomon & Ludwin LLC

Salomon & Ludwin LLC lifted its stake in shares of Danaher Co. (NYSE:DHR) by 32.4% during the first quarter, Holdings Channel.com reports. The fund owned 405 shares of the conglomerate’s stock after purchasing an additional 99 shares during the period. Salomon & Ludwin LLC’s holdings in Danaher were worth $101,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in the business. Alpine Global Management LLC acquired a new stake in Danaher in the 3rd quarter valued at approximately $1,489,000. Townsquare Capital LLC increased its holdings in shares of Danaher by 15.6% in the third quarter. Townsquare Capital LLC now owns 9,524 shares of the conglomerate’s stock worth $2,363,000 after acquiring an additional 1,288 shares in the last quarter. Belpointe Asset Management LLC increased its position in shares of Danaher by 36.5% during the third quarter. Belpointe Asset Management LLC now owns 4,002 shares of the conglomerate’s stock worth $993,000 after acquiring an additional 1,070 shares in the last quarter. BRYN MAWR TRUST Co raised its position in Danaher by 1.7% in the 3rd quarter. BRYN MAWR TRUST Co now owns 4,797 shares of the conglomerate’s stock valued at $1,190,000 after buying an additional 81 shares during the last quarter. Finally, Creative Planning grew its position in Danaher by 14.9% in the third quarter. Creative Planning now owns 107,895 shares of the conglomerate’s stock valued at $26,769,000 after purchasing an additional 13,987 shares in the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.

Wall Street Analyst Weigh In

DHR has been the topic of several research analyst reports. Barclays increased their price objective on shares of Danaher from $260.00 to $270.00 and gave the company an “equal weight” rating in a research report on Wednesday, April 24th. TD Cowen raised their target price on shares of Danaher from $280.00 to $290.00 and gave the company a “buy” rating in a research report on Wednesday, April 24th. StockNews.com cut shares of Danaher from a “buy” rating to a “hold” rating in a research report on Tuesday, June 25th. Jefferies Financial Group assumed coverage on Danaher in a report on Monday, June 3rd. They issued a “buy” rating and a $295.00 target price on the stock. Finally, HSBC raised Danaher from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $250.00 to $280.00 in a research report on Wednesday, April 17th. Six analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $268.67.

Danaher Trading Down 0.4 %

Shares of Danaher stock traded down $0.86 on Tuesday, hitting $239.79. 1,937,876 shares of the company traded hands, compared to its average volume of 2,866,813. The stock’s 50 day moving average price is $255.29 and its 200-day moving average price is $247.29. The company has a market cap of $177.61 billion, a PE ratio of 40.54, a PEG ratio of 3.66 and a beta of 0.83. Danaher Co. has a 52 week low of $182.09 and a 52 week high of $269.11. The company has a current ratio of 1.85, a quick ratio of 1.51 and a debt-to-equity ratio of 0.31.

Danaher (NYSE:DHR) last posted its earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.72 by $0.20. The company had revenue of $5.80 billion for the quarter, compared to analyst estimates of $5.62 billion. Danaher had a return on equity of 11.43% and a net margin of 16.78%. The firm’s quarterly revenue was down 2.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.36 earnings per share. Equities research analysts predict that Danaher Co. will post 7.63 EPS for the current year.

Danaher Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, July 26th. Shareholders of record on Friday, June 28th will be given a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a yield of 0.45%. The ex-dividend date of this dividend is Friday, June 28th. Danaher’s dividend payout ratio is presently 18.31%.

Insider Buying and Selling at Danaher

In related news, Director Alan G. Spoon sold 708 shares of the company’s stock in a transaction dated Thursday, May 2nd. The stock was sold at an average price of $243.58, for a total value of $172,454.64. Following the completion of the transaction, the director now owns 116,202 shares of the company’s stock, valued at approximately $28,304,483.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, CEO Rainer Blair sold 47,175 shares of the stock in a transaction on Wednesday, April 24th. The stock was sold at an average price of $249.22, for a total transaction of $11,756,953.50. Following the completion of the transaction, the chief executive officer now directly owns 115,995 shares in the company, valued at approximately $28,908,273.90. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Alan G. Spoon sold 708 shares of the company’s stock in a transaction that occurred on Thursday, May 2nd. The stock was sold at an average price of $243.58, for a total transaction of $172,454.64. Following the completion of the transaction, the director now owns 116,202 shares in the company, valued at $28,304,483.16. The disclosure for this sale can be found here. In the last ninety days, insiders sold 148,783 shares of company stock worth $37,536,717. Company insiders own 10.90% of the company’s stock.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.